EPO in traumatic brain injury: Two strikes⋯but not out?

The Lancet

Volumn 386, Issue 10012, 2015, Pages 2452-2454

  Menon, David K ^a   Maas, Andrew I R ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

CLINICAL RESEARCH; DRUG EFFECT; GLASGOW OUTCOME SCALE; HUMAN; INTENSIVE CARE UNIT; INTRACRANIAL PRESSURE; MORTALITY; NEUROPROTECTION; NOTE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL; THROMBOEMBOLISM; TRAUMATIC BRAIN INJURY; BRAIN INJURIES; FEMALE; MALE;

BRAIN INJURIES; ERYTHROPOIETIN; FEMALE; HUMANS; MALE;

EID: 84956584079     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00387-6     Document Type: Note

References (10)

1. T Janowitz, DK Menon Exploring new routes for neuroprotective drug development in traumatic brain injury Sci Transl Med 2 2010 27rv1
2. LL Ponce, JC Navarro, O Ahmed, CS Robertson Erythropoietin neuroprotection with traumatic brain injury Pathophysiology 20 2013 31 38
3. A Nichol, C French, L Little for the EPO-TBI Investigators and the ANZICS Clinical Trials Group Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial Lancet 2015 published online Oct 7. http://dx.doi.org/10.1016/S0140-6736(15)00386-4
4. EW Steyerberg, N Mushkudiani, P Perel et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics PLoS Med 5 2008 e165
5. CS Robertson, HJ Hannay, JM Yamal et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial JAMA 312 2014 36 47
6. HL Corwin, A Gettinger, TC Fabian et al. Efficacy and safety of epoetin alfa in critically ill patients N Engl J Med 357 2007 965 976
7. B Jennett, M Bond Assessment of outcome after severe brain damage Lancet 1 1975 480 484
8. US Food and Drug Administration Prescribing information. Epogen (epoetin alfa) for intravenous or subcutaneous use http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103234s5323lbl.pdf 2013 (accessed Oct 1, 2015).
9. M Collino, C Thiemermann, A Cerami, M Brines Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin Pharmacol Ther 151 2015 32 40
10. AIR Maas, DK Menon, EW Steyerberg on behalf of the CENTER-TBI Participants and Investigators Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study Neurosurgery 76 2015 67 80